imagem top

2023

ANUÁRIO DO HOSPITAL
DONA ESTEFÂNIA

CHULC LOGOlogo HDElogo anuario

MEMORY B CELL ACTIVATION INDUCED BY PERTUSSIS BOOSTER VACCINATION IN FOUR AGE GROUPS OF THREE COUNTRIES

Pauline Versteegen1, Alex-Mikael Barkoff2, Marta Valente Pinto3, Jan van de Kasteele1, Aapo Knuutila2, Sagida Bibi3, Lia de Rond1, Johanna Teräsjärvi2, Katherine Sanders3, Mary-lène de Zeeuw-Brouwer1, Raakel Luoto2, Hinke ten Hulscher1, Elizabeth A. Clutterbuck3, Elisabeth A. M. Sanders1,4, Jussi Mertsola2, Guy A. M. Berbers1, Qiushui He2, Dominic F. Kelly3,5, Anne-Marie Buisman1 and PERISCOPE Consortium

1 - National Institute for Public Health and the Environment, Centre for Infectious Disease Control, Bilthoven, Netherlands,
2 - Institute of Biomedicine, Microbiology, Virology and Immunology, and Turku University Hospital, University of Turku, Turku, Finland,
3 - Department of Paediatrics, Oxford Vaccine Group, University of Oxford, Oxford, United Kingdom,
4 - Department of Paediatric Immunology and Infectious Diseases, Wilhelmina Children’s Hospital, Utrecht, Netherlands,
5 - Oxford NIHR Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom;

- Front. Immunol. 13:864674.

Background: Immunogenicity of acellular pertussis (aP) vaccines is conventionally assessed by measuring antibody responses but antibody concentrations wane quickly after vaccination. Memory B cells, however, are critical in sustaining long-term protection and therefore may be an important factor when assessing pertussis immunity after vaccination.
Aim: We studied pertussis specific memory B cell (re)activation induced by an aP booster vaccination in four different age groups within three countries.
Materials and methods: From a phase IV longitudinal interventional study, 268 participants across Finland, the Netherlands and the United Kingdom were included and received a 3-component pertussis booster vaccine: children (7-10y, n=53), adolescents (11-15y, n=66), young adults (20-34y, n=74), and older adults (60-70y, n=75). Memory B cells at baseline, day 28, and 1 year post-vaccination were measured by a pertussis toxin (Ptx), filamentous haemagglutinin (FHA), and pertactin (Prn) specific ELISpot assay. Antibody results measured previously were available for comparison. Furthermore, study participants were distributed into groups based on their baseline memory B cell frequencies, vaccine responses were monitored between these groups.
Results: Geometric mean (GM) memory B cell frequencies for pertussis antigens at baseline were low. At 28 days post-vaccination, these frequencies increased within each age group and were still elevated one year post-booster compared to baseline. Highest frequencies at day 28 were found within adolescents (GM: 5, 21, and 13, for Ptx, FHA and Prn, respectively) and lowest within older adults (GM: 2, 9, and 3, respectively). Moderate to strong correlations between memory B cell frequencies at day 28 and antibody concentrations at day 28 and 1 year were observed for Prn. Memory B cell frequencies > 1 per 100,000 PBMCs at baseline were associated with significantly higher memory responses after 28 days and 1 year.
Conclusions: An aP booster vaccine (re)activated memory B cells in all age groups. Still elevated memory B cell frequencies after one year indicates enhanced immunological memory. However, antigen specific memory B cell activation seems weaker in older adults, which might reflect immunosenescence. Furthermore, the presence of circulating memory B cells at baseline positively affects memory B cell responses.

Keywords: pertussis, memory B cells, vaccination, longitudinal, children, adolescents, adults, older adults